Business Wire

STARLIMS Launches QM Essentials LIMS, the Best Cloud LIMS for SMB Batch Manufacturing

21.10.2025 15:13:00 CEST | Business Wire | Press Release

Share

STARLIMS, a global leader in Laboratory Information Management Systems (LIMS) and informatics solutions, today announced Quality Manufacturing (QM) Essentials, a new cloud-based LIMS developed for small and mid-sized (SMB) batch manufacturers to bring products to market quickly and more cost-effectively.

The launch reflects STARLIMS’ commitment to meeting the unique needs of smaller batch manufacturing organizations who need the power of a LIMS without the cost or complexity of a large-scale implementation. Built for pharmaceutical, food & beverage, and consumer product industries, QM Essentials allows SMBs to simplify compliance and expedite batch release with an out-of-the-box solution that can be deployed in as little as 4-6 weeks.

A Cost-Effective SaaS LIMS with Less Complexity

Pre-configured and pre-loaded with essential features such as batch login, environmental monitoring, outsource samples, and static data, QM Essentials is a Software-as-a-Service (SaaS) LIMS that allows SMB labs to get started fast, while minimizing costs and avoiding the need for expensive, custom solutions. The LIMS also includes pre-configured roles, allowing manufacturers to quickly automate and streamline their labs to get to market faster.

“With the QM Essentials LIMS, we’re bringing STARLIMS’ decades of expertise to smaller manufacturers who face the same quality and compliance pressures as large enterprises, but need a less complex solution,” said Lauren Whitsell, Chief Product & Operations Officer at STARLIMS. “QM Essentials allows SMBs to improve lab efficiency, productivity, and traceability with a cost-effective, scalable LIMS designed to do more, with less.”

Built on Proven STARLIMS Technology

QM Essentials distills years of proven LIMS technology into a less complex, scalable system, giving SMB manufacturers the flexibility to start small and seamlessly expand to the full-featured Quality Manufacturing (QM) LIMS as their needs evolve—without the need for a major system migration.

Optional STARLIMS solution extensions such as Stability Studies and Advanced Analytics 2.0 are also available for organizations that want to expand capabilities and gain deeper insights into lab performance.

Delivering Lab Excellence for Nearly Four Decades

QM Essentials reflects STARLIMS’ continued investment in helping organizations of all sizes modernize lab operations. With years of experience supporting global enterprise manufacturing leaders, STARLIMS is excited to extend those benefits to smaller manufacturers seeking agility, efficiency, and optimization at scale.

To learn more about QM Essentials or request a demo, visit starlims.com.

About STARLIMS

As a recognized leader in LIMS and informatics solutions, STARLIMS is committed to providing quality products and services to over 1,100 customers across the globe. Found in 2,000+ laboratories, STARLIMS serves life sciences, CDMOs, food & beverage, chemical, agrochemical, oil & gas, consumer goods, contract testing, R&D, public health, and clinical diagnostics organizations. With a modern R&D ELN incorporated into its portfolio, STARLIMS addresses the critical challenges customers face in finding an advanced platform that supports them from R&D through commercialization.

View source version on businesswire.com: https://www.businesswire.com/news/home/20251021778402/en/

Contacts

Brette Querzoli, Senior Marketing Director
STARLIMS
Brette.querzoli@starlims.com

(c) 2024 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Imagine Dragons to Perform at Abu Dhabi Grand Prix21.5.2026 17:51:00 CEST | Press Release

Ethara, organiser of the Formula 1 Etihad Airways Abu Dhabi Grand Prix, have announced that one of the world’s biggest bands, Imagine Dragons, will headline the Saturday After-Race Concerts at the F1 Season Finale in Abu Dhabi. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521214839/en/ Imagine Dragons to perform at Formula 1 Etihad Airways Abu Dhabi Grand Prix (Photo: AETOSWire) The announcement is another landmark moment for the Abu Dhabi Grand Prix, whose thrilling Yasalam presented by e& fan entertainment offering has become synonymous with the F1 Championship finale in Abu Dhabi and is recognised as one of the most compelling sports and entertainment crossovers globally. The global chart-toppers join Lewis Capaldi and Zara Larsson, who are set to kick off a blockbuster line-up of performances on Yas Island on Thursday, 3 December, with more major international artists to be revealed. With their popular top hits, Ima

Otovo Hits 30,000 Customers in Under a Year, Tackling the Growing ‘Solar Service Crisis’21.5.2026 16:25:00 CEST | Press Release

Otovo ASA (“Otovo”), a leading global energy service provider for residential and commercial customers, today announced it has reached 30,000 customers across the U.S. and Europe. A total of 20,000 customers have enrolled in Otovo Care, the Company’s membership-based home and commercial energy service, which is powered by Otovo’s industry-leading AI platform, Endurance™. “Reaching 30,000 customers in less than year is proof positive that home and business owners value their power systems,” said William J. (John) Berger, CEO of Otovo. “The ‘solar service crisis’ that is leaving millions of orphaned energy systems without support is driving strong interest in our Otovo Care membership program. Every day your home or commercial power system is not working, you are throwing money away. Otovo’s rapid response service platform keeps you up and running, ensuring your investment is delivering.” The rapid growth of the residential solar market created a growing population of “orphaned” solar sy

Carnegie Mellon University and Cleveland Clinic Develop AI System to Interpret Cardiac MRI Scans with Enhanced Accuracy21.5.2026 14:05:00 CEST | Press Release

A team of researchers from Carnegie Mellon University, in collaboration with Cleveland Clinic’s Cardiovascular Innovation Research Center, has developed an artificial intelligence (AI) system capable of interpreting some of the most complex heart scans in medicine, cardiac magnetic resonance imaging (MRI), without the need for manually labeled training data. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521762286/en/ A team of researchers from Carnegie Mellon University, in collaboration with Cleveland Clinic’s Cardiovascular Innovation Research Center, has developed an artificial intelligence (AI) system capable of interpreting some of the most complex heart scans in medicine, cardiac magnetic resonance imaging (MRI), without the need for manually labeled training data. The novel system, called CMR-CLIP, is designed to interpret cardiac MRI scans by connecting moving images of the heart with corresponding clinical radio

The Live Moment Effect: Genius Sports and MediaScience Study Finds Specific Moments in Live Sports Can Double Unaided Brand Recall21.5.2026 14:00:00 CEST | Press Release

Genius Sports Limited (NYSE: GENI), a global leader in real-time sports data, today released new biometric research conducted with MediaScience showing that ads delivered immediately after emotionally heightened moments in live sports can double unaided brand recall. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521475265/en/ The Live Moment Effect report from Genius Sports and MediaScience. The study, The Live Moment Effect, finds that advertising effectiveness is significantly influenced by a viewer’s emotional state immediately before an ad is shown. In controlled biometric testing, ads shown after high-intensity sporting moments, such as near-scoring plays or crucial momentum shifts, delivered approximately double the unaided brand recall of baseline conditions. The Moment Before the Ad Matters The research challenges long-held assumptions about media value, showing that not all impressions are equal. Live sports rem

Merck Announces First Patient Dosed in Phase 3 Study for Investigational Antibody-Drug Conjugate in Colorectal Cancer21.5.2026 14:00:00 CEST | Press Release

Merck, a leading science and technology company, today announced that the first patient has been dosed in the Phase 3 PROCEADE®-CRC-03 trial (NCT07549412). The study is evaluating precemtabart tocentecan (Precem‑TcT), a potential first‑in‑class investigational anti‑CEACAM5 antibody‑drug conjugate (ADC), for the treatment of metastatic colorectal cancer (mCRC). “Leveraging our novel payload‑linker technology, Precem‑TcT is the first CEACAM5‑targeted ADC in clinical studies with an exatecan payload, rationally designed for stability and enhanced cancer cell killing activity,” said David Weinreich, MD, MBA, Global Head of R&D and Chief Medical Officer for the Healthcare business of Merck. “The Phase 3 study and the enrollment of the first patient with Precem-TcT build on the Company’s more than 20 years of expertise in colorectal cancer, and highlight our commitment to advancing differentiated ADCs for heavily pretreated patients with limited treatment options.” The PROCEADE®-CRC-03 study

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye